Infliximab
Brand name: Remicade
Rank #381 of 500 drugs by total cost
$25.3M
Total Cost
3,457
Total Claims
$25.3M
Total Cost
164
Prescribers
$7,316
Cost per Claim
154
Beneficiaries
4,534
30-Day Fills
$154K
Avg Cost/Provider
21
Avg Claims/Provider
About Infliximab
Infliximab (sold as Remicade) was prescribed 3,457 times by 164 Medicare Part D providers in 2023, costing the program $25.3M. At $7,316 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 378 | Ponatinib Hcl (Iclusig) | $25.6M | 1,209 |
| 379 | Citalopram Hydrobromide (Citalopram Hbr) | $25.3M | 2,778,255 |
| 380 | Amoxicillin/Potassium Clav (Amoxicillin-Clavulanate Potass) | $25.3M | 2,207,997 |
| 381 | Infliximab (Remicade) | $25.3M | 3,457 |
| 382 | Glimepiride (Glimepiride) | $25.3M | 1,885,737 |
| 383 | Flecainide Acetate (Flecainide Acetate) | $25.1M | 412,334 |
| 384 | Pioglitazone Hcl (Pioglitazone Hcl) | $24.8M | 1,182,614 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology